The Heifets Laboratory
Welcome to the Heifets Lab
Our research group is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. We bridge basic science and clinical trials, connecting neuroscience, psychiatry and anesthesiology in pursuit of highly effective, safe treatment strategies scalable to the millions of patients who need them.
Follow Us on Twitter
I am looking for someone to join @Psyched_Alpha to research and write about psychedelic drug development and roll-out with me.
Do you know someone? Please let me know!
Psychedelic Alpha | Research Analyst / Writer - Psychedelic Drug Development & Clinical Rollout...
Psychedelic Alpha is seeking a part-time analyst to support our coverage of psychedelic drug development...
jobs.psychedelicalpha.com
Directional elements: the preprints are out! Congratulations to our amazing team linked here:
https://www.biorxiv.org/content/10.64898/2026.05.27.726039v2
https://www.biorxiv.org/content/10.64898/2026.05.27.726038v1
https://www.biorxiv.org/content/10.64898/2026.05.27.728040v1
We screened for principles governing global brain dynamics by developing a set of new methods: 1) conformal
Introduce yourself with 10 bands you’ve seen live:
Pink Floyd
Radiohead
Spiritualized
Fugazi
Metallica
Cibo Matto
Pigface
The Jesus Lizard
P-Funk
Rob Base
Introduce yourself with 10 bands you've seen live:
Pink Floyd
David Bowie
Bob Dylan
Mark Knopfler
Dead can Dance
Massive Attack
Rolling Stones
Nine Inch Nails
Siouxie & The Banshees
Air
🧵 Targeting sleep to treat depression: New mechanistic insights from the TIRED Study
Thrilled to share our first major paper in @npp_journal ! Led by Adam Krause, we examined how CBT-I improves depression in people with comorbid insomnia.
🔗 https://www.nature.com/articles/s41386-026-02431-0
1/n
A low dose of opioid-partial agonist buprenorphine sustained the anti-suicide effects of a single-ketamine dose in new one-month RCT.
Small study, blind somewhat intact.
But no, it's not a long-term replacement for ketamine. Read why:
https://psych-partners.com/a-drug-that-sustains-ketamines-benefits
"When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities"
When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsi...
Aided by COVID-19–era regulatory flexibilities, direct-to-consumer telemedicine has expanded access to mental health care....
psychiatryonline.org
DREADDs in humans--update:
3 clinical trials using hM4Di in humans registered in China. 2 for epilepsy and 1 for Parkinson's Disease.
In our original paper we stated:
"...We suggest that at least one of these designer receptors, hM4D, will prove useful for neuronal silencing in
A few months ago, @ResearchHub contacted me about joining the team.
I wasn’t really looking for work.
This is what made me take a closer look 👇
The Endowments feature they just launched is unreal, for scientists *and* anyone who supports science
(1/4)
New publication! 🧠
Excited to share our latest paper, for which I am co-first author. This randomized controlled trial provides the first evidence that #buprenorphine can prolong and augment #ketamine’s antisuicidal effects in depression.
https://doi.org/10.1176/appi.ajp.20250840
